The pharmaceutical industry has called for abolishing “off-year” drug price revisions in the run-up to the formulation of the 2024 Basic Policy on Economic and Fiscal Management and Reform (honebuto) later in June. It appears that its lobbying efforts have…
HOME > LATEST
LATEST
-
REGULATORY Health Minister Set to Meet Generic Execs to Hear Views on Industry Revamp
June 26, 2024
-
BUSINESS TGCV Drug CNT-01 Misses Goal in Japan PIIb/III Study: Toa Eiyo
June 26, 2024
-
BUSINESS Tagrisso Plus Chemo Now Allowed to Treat EGFR Lung Cancer: AstraZeneca
June 26, 2024
-
BUSINESS JCR, Takeda End Global Collab for Hunter Syndrome Therapy
June 26, 2024
-
BUSINESS Rexulti’s PTSD Filing Clinches FDA Acceptance for Review: Otsuka/Lundbeck
June 26, 2024
-
BUSINESS Santen CEO Snares 191 Million Yen in Annual Pay, Workforce Down by 131
June 26, 2024
-
BUSINESS Finnish Pharma Orion Poised for Japan Debut with Reacquisition of Parkinson’s Meds This Year
June 26, 2024
-
BUSINESS AnGes Alters Strategy for Collategene, Halts Japan Sales for Fresh Submission
June 25, 2024
-
REGULATORY Japan's First Eylea Biosimilar Wins Nod, Potential Listing in November
June 25, 2024
-
REGULATORY Health Ministry Changes Avigan Approval Conditions
June 25, 2024
-
REGULATORY Japan Approves Novartis’ Fabhalta, Lilly’s Jaypirca, and Lots More
June 25, 2024
-
BUSINESS Recordati Japan Names Shoji Kuroyama as New President
June 25, 2024
-
BUSINESS Takeda Scores EU Approval for Colorectal Cancer Med Fruzaqla
June 25, 2024
-
BUSINESS BMS Gears Up for Return to Neuroscience with KarXT, Explores Path toward Japan Rollout Too
June 25, 2024
-
REGULATORY Japan OKs Honebuto Paper, Modest Wording on Off-Year Revisions Finalized
June 24, 2024
-
ACADEMIA Academic Society Frets Availability of 1st-Gen Oral Cephems amid Choseido Halt
June 24, 2024
-
REGULATORY Japan to Obligate Single IRB in Multi-Center Clinical Trials That Use Competitive Funds
June 24, 2024
-
REGULATORY PMDA Reviewing Safety Risks for Duvroq, Opdivo, and More
June 24, 2024
-
BUSINESS Shionogi Workforce Down 341 after Voluntary Buyout Program
June 24, 2024
-
ORGANIZATION Japan Digital Health Alliance Keen to Boost Ties with Overseas Organizations
June 21, 2024
ページ
The pharmaceutical industry is ever-changing. Recruiters must evolve accordingly and prepare well in advance for future talent needs.This means predicting the changes and trends that will impact the market, industry, and your organization, and how this will affect talent requirements.…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…